Back HCV Treatment Experimental HCV Drugs

Experimental HCV Drugs

European Regulators Approve Daclatasvir for Hepatitis C

The European Medicines Agency, which handles regulatory approval for 28 countries of the European Union, this week approved Bristol-Myers Squibb's hepatitis C virus NS5A inhibitor daclatasvir (Daklinza) for use in combination therapy for HCV genotypes 1, 2, 3, and 4.

alt

Read more:

Achillion HCV NS5A Inhibitor + Sofosbuvir Shows High Early Cure Rate

An interferon-free dual combination of Achillion's hepatitis C virus NS5A inhibitor ACH-3012 plus Gilead Science's HCV polymerase inhibitor sofosbuvir (Sovaldi) taken for 8 weeks led to sustained virological response at 4 weeks post-treatment for people with HCV genotype 1 in a Phase 2 study, according to a company announcement.

alt

Read more:

AIDS 2014: AbbVie Hepatitis C Treatment Works Well for People on Methadone or Buprenorphine

People with chronic hepatitis C who are using methadone or buprenorphine to manage opiate addiction can be safely and effectively treated with AbbVie's 3D all-oral direct-acting antiviral regimen plus ribavirin, resulting in a 97% cure rate, according to a report this week at the 20thInternational AIDS Conference in Melbourne.People with chronic hepatitis C who are using methadone or buprenorphine to manage opiate addiction can be safely and effectively treated with AbbVie's 3D all-oral direct-acting antiviral regimen plus ribavirin, resulting in a 97% cure rate, according to a report this week at the 20thInternational AIDS Conference in Melbourne.

alt

Read more:

Studies Show High Cure Rates for Interferon-free Hepatitis C Treatment

An all-oral combination of daclatasvir (Daklinza) plus asunaprevir led to sustained virological response (SVR) in 82%-90% of treatment-naive and previously treated people with hepatitis C virus genotype 1b, while a regimen of sofosbuvir (Sovaldi) plus simeprevir (Olysio) cured 92%-94% of hepatitis C patients with or without cirrhosis, according to findings from a pair of clinical trials reported in the July 28 advance online edition of The Lancet.

alt

Read more:

Coverage of the 2014 International AIDS Conference

HIVandHepatitis.com coverage of the 20th International AIDS Conference (AIDS 2014), July 20-25, in Melbourne, Australia.

Conference highlights include biomedical HIV prevention (PrEP and treatment-as-prevention), HIV cure research, interferon-free therapy for hepatitis C and HIV/HCV coinfection, access to treatment, and fighting stigma and criminalization of key affected populations.

Full listing by topic

7/25/14

alt